Silence Therapeutics PLC ADR (SLN)
Silence Therapeutics PLC ADR is a depositary receipt listed on NASDAQ that reflects the common shares of Silence Therapeutics plc, a biotechnology company focused on RNA interference, or siRNA, research and development. The company is working on therapies intended to affect gene expression in areas such as hematology, cardiovascular disease, and rare diseases. Its pipeline includes Divesiran (SLN124), which is being studied in Phase 2 for polycythemia vera, along with SLN548 for complement-mediated renal diseases. Additional programs include Zerlasiran (SLN360) for cardiovascular disease linked to elevated lipoprotein(a), as well as SLN312, SLN365, and SLN098 for dyslipidemia, hypercholesterolemia, and obesity. The company was founded in 1994, is based in London, and adopted the Silence Therapeutics plc name in 2007.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SLN
|
$11.36
|
-42.7% Downside
|
Overvalued
|
$19.75
|
-0.4% Downside
|
Fair
|
Fair
|
0.0%
|
March 17, 2027
|
32.0x
|
2,002.6x
|
1.233 B
|
1.16 B
|
0.0%
|
85.6%
|
-15.3
|
70.5%
|